Endodiag

Endodiag is a pioneering diagnostics company dedicated to transforming the endometriosis care pathway. The company is developing a multi-pronged approach, including a first-of-its-kind blood test for early diagnosis, a solution for mapping the disease to guide surgical and therapeutic decisions, and leveraging its biomarker expertise to support novel drug development. Operating in a field with major diagnostic delays and no cure, Endodiag targets a large, underserved patient population (affecting ~10% of women) with solutions intended for healthcare professionals. Its work has been recognized through nominations for industry awards like the Galien Medstartup prize.

Biomarker discovery and validation platform for endometriosis, focused on blood-based molecular diagnostics for detection, disease mapping, and therapy support.

The competitive landscape for non-invasive endometriosis diagnostics is emerging but not yet crowded. Competition comes from other biotech startups and academic groups researching biomarkers (e.g., in blood, menstrual fluid). Endodiag's integrated approach spanning diagnosis, guidance, and therapy support may differentiate it from players focused solely on a detection test.